UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot
Business live – latest updates
AstraZeneca said it was shifting the production of some medicines sold in the US from Europe to the US, to counter the impact of Donald Trump’s trade tariffs.
Speaking as the company reported higher sales and profits for the first quarter, the FTSE 100 pharma company reiterated that the UK, and the rest of Europe, risked losing out to the US and China unless they ramped up spending on new medicines. Pascal Soriot, AstraZeneca’s chief executive, warned that well-paid advanced manufacturing and research jobs could move to the US in the long run.
About Author
More Stories
Labor loses $1bn from Victoria’s upcoming budget surplus in favour of ‘practical’ cost-of-living relief
Trump says he has a ‘little problem’ with Tim Cook over Apple’s India production
Son Heung-min tells South Korean police he is victim of blackmail attempt